RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07824882, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).

    Inclusion criterion 3

  3. Prior or current treatment targeting B7-H3;

    Exclusion criterion 3

  4. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1.

    Inclusion criterion 5

  5. Prior pathological diagnosis of mixed non-small cell lung cancer or any transformed non-small cell lung cancer.

    Exclusion criterion 1

  6. Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.

    Inclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07824882, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 years at the time of informed consent form (ICF) signature, either sex.
  • Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent, and commitment to comply with all requirements specified in this clinical trial protocol.
  • Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
  • Presence of at least one measurable target lesion.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1.
  • Minimum life expectancy >12 weeks.
  • Adequate organ function.
  • Absence of the following active infectious diseases: hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, tuberculosis, or syphilis.
  • Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.

Exclusion Criteria:

  • Prior pathological diagnosis of mixed non-small cell lung cancer or any transformed non-small cell lung cancer.
  • Prior or ongoing treatment with any of the following:
  • Prior or current treatment targeting B7-H3;
  • Prior or current treatment with topoisomerase I inhibitor agents, including antibody-drug conjugates with topoisomerase I inhibitor payloads, etc.;
  • Prior treatment with docetaxel monotherapy or in combination with other agents.
  • Persistent adverse reactions caused by prior treatment.
  • Untreated brain metastases; uncontrolled brain metastases; presence of leptomeningeal or brainstem metastases; presence of spinal cord compression (identified by radiographic imaging, regardless of symptoms).
  • History of other primary malignancies.
  • Presence of any of the following abnormal cardiac findings:
  • Evidence of currently clinically significant important arrhythmia or ECG abnormality;
  • Presence of risk factors causing QT interval prolongation or arrhythmic events.
  • Severe, uncontrolled, or active cardiovascular or cerebrovascular disease.
  • Severe or poorly controlled hypertension.
  • Severe or poorly controlled diabetes mellitus.
  • Clinically significant bleeding symptoms or significant bleeding tendency.
  • Severe infection.
  • History of severe arterial or venous thromboembolic events.
  • Known or suspected interstitial pneumonitis, immune-mediated pneumonitis, or radiation pneumonitis.
  • Participants with active or history of autoimmune disease with potential for recurrence.
  • Prior occurrence of severe or life-threatening immune-mediated adverse events.

Quoted from ClinicalTrials.gov, NCT07824882, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07824882, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07824882